Xflot
Dilip Buildcon wins a Rs 1,800 crore LPG pipeline from Paradip to Raipur, to build in three years and run for 25Jubilant FoodWorks puts September-quarter revenue at Rs 2,609 crore, up 11.9%; Domino's India same-store sales rise 4.1%Ola Electric sets a Rs 999.74 crore rights issue at Rs 27 a share, two for every 25 held; record date October 13Brent rises to $101.50 as a Gulf of Mexico storm threatens 15% of US crude output and fighting flares in YemenFed minutes: most officials saw one more rate increase by year-end; they split on why they raised in SeptemberNewly listed ARCIL hits the 10% upper limit after first-quarter profit doubles; Kanohar Electricals rises 20%Fusion CX is reported to be launching a Rs 700-800 crore IPO next week, cut from Rs 1,000 crore plannedAirtel raises every postpaid plan by Rs 50 from October 8; the entry plan goes to Rs 499 from Rs 449Chennai Petroleum jumps 14.6% and MRPL 4.7% as Brent climbs back above $101 a barrelSensex ends 429 points lower at 72,639 after the RBI increase; the metal index drops 2.3%, PSU banks and media gain
Nifty 50 23,146.15 +0.65%Nifty Bank 55,844 +0.06%Nifty Midcap 150 21,736.75 −0.09%Nifty Smallcap 250 17,637.65 +0.06%Nifty IT 31,924.1 +3.92%India VIX 14.08 +0.35%NSE indices →

Business news · Global · 29 Sept 2026

US 100% tariff on patented drugs starts Sept 29; generics stay outside it and India gets zero duty on select specialty medicines

IN Healthcare

What happened

Washington's 100% Section 232 tariff on specified patented medicines took effect on September 29. The US Commerce Department put India among 20 jurisdictions eligible for zero duty on certain specialty products: orphan drugs for rare diseases, fertility treatments, cell and gene therapies, antibody-drug conjugates and veterinary medicines. The relief covers specific products and is not a blanket exemption. India's pharma exports were $31.1 billion in FY26, of which $9.47 billion (30.4%) went to the US.

Why it matters for listed companies

The US is the largest single export market for Indian drugmakers. Most of what they ship there is generics, and the Commerce Department said generics and their ingredients fall outside the Section 232 tariff. That leaves their exposure limited to branded and specialty lines. The report names Sun Pharma, Dr Reddy's, Cipla, Biocon, Zydus Life, Shilpa Medicare and Hester Bio as the companies in focus. Firms with patented or specialty products in the US that are not on the zero-duty list still face the 100% rate on those products.

Reported by Business Today — “Pharma stocks: Sun Pharma, Dr Reddy's, Cipla, Biocon and others in focus today; here's why” ↗ on 29 Sept 2026.

How these sectors have moved since

NSE stocks, from the last close on or before 29 Sept 2026 to the close on 16 Oct 2026.

SectorStocksMedian moveUpvs all stocks
Healthcare74 -6.5%4 of 74-4.6 pts
All tracked stocks804-1.9%307 of 804—

Companies named in the report

CompanyThenNowMove
Biocon Ltd. BIOCON ₹377₹349.2 -7.4%
Hester Biosciences Limited HESTERBIO ₹2,165₹2,236.5 +3.3%
Shilpa Medicare Ltd. SHILPAMED ₹1,055.75₹937.6 -11.2%
Zydus Lifesciences Ltd. ZYDUSLIFE ₹1,200.5₹1,123 -6.5%
Sun Pharmaceutical Industries Ltd. SUNPHARMA ₹1,865₹1,758.8 -5.7%
Cipla Ltd. CIPLA ₹1,379.3₹1,325.1 -3.9%
Dr. Reddy's Laboratories Ltd. DRREDDY ₹1,251.9₹1,233 -1.5%
These figures are measured, not attributed. Prices and rates move for many reasons at once; they show what happened after this story, not that the story caused it. Nothing here is a recommendation to buy, sell or hold.

More on Healthcare

All business stories · Every market · What changed today

Free · one email a day

Market briefs, by country

Pick the markets you follow. Each morning: what changed, in figures — never a tip.

Markets

Free. We email a link to confirm — nothing is sent until you click it. Every brief has a one-click unsubscribe that deletes your record. Data, not advice: XDQ Labs is not registered with SEBI, the US SEC, FINRA or any European regulator. GMP is unofficial. Privacy. Sent daily at 08:15 India time.